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Tacrolimus a macrolide immunosuppressant that is
routinely given in two equally divided doses every
12 h. However, the time-dependent pharmacokinet-
ics of tacrolimus suggest that once daily morning ad-
ministration of tacrolimus may produce appropriate
drug exposure. The purpose of this pilot study was
to compare the pharmacokinetics and safety of twice
vs. once daily administration of tacrolimus in stable
kidney transplant recipients. Steady-state tacrolimus
pharmacokinetic parameters were estimated on two
occasions in an open-label, three-arm, two-period se-
quential study: twice daily dosing (Phase I) and once
daily dosing (Phase II). In phase II, 18 patients were as-
signed to one of three arms: those taking 67%, 85%
and 100% of their total twice daily dose once in the
morning. In phase I, the mean area under the blood
concentration–time curve (AUC) was higher after the
morning dose, AUC 0–12 117 ± 40 vs. AUC 12–24 97 ±
30 ng/h/mL, p = 0.012. In the 85% Group, the mean
AUC ratio between twice and once daily was 1.0 (95%
CI, 0.9–1.1) which predicted the best conversion ratio.
Tacrolimus given once daily in the morning, at 85% of
the twice daily dose, provides safe and equivalent drug
exposure to twice daily dosing. This convenient dosing
schedule may help to increase compliance and lower
costs.
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Introduction
The availability of calcineurin inhibitors has revolutionized
the practice of transplantation by lowering acute rejection
rates and improving short-term graft survival. Available cal-
cineurin inhibitors include tacrolimus (Prograf®, Fujisawa
Healthcare, Inc., Deerfield, IL, USA) and cyclosporine that
are both Food and Drug Administration (FDA) approved for
administration in two equally divided doses every 12 h.
Routinely, tacrolimus and cyclosporine doses have been
titrated based on blood trough concentrations and clinical
assessments of rejection and tolerability.
Although cyclosporine trough level is routinely used in
therapeutic monitoring due to convenience, it correlates
poorly with systemic drug exposure and clinical out-
comes (1–4). In contrast, tacrolimus trough concentra-
tions (Cmin) have been found to correlate well with the
area under the blood concentration–time curve (AUC)
which reflects total body exposure to the drug (5). Also,
a good correlation between clinical outcomes and the
tacrolimus Cmin has been observed in clinical trials (6–
9). A 2-h post-dose cyclosporine level (C2) has been pro-
posed as a more reliable tool to monitor cyclosporine
therapy because C2 has a better correlation with AUC
than cyclosporine trough level (10–12). However, unlike cy-
closporine C2 levels, tacrolimus peak concentration (Cmax.)
has not been routinely utilized to predict rejection or
toxicity (9).
Transplant clinicians generally assume that equivalent
peak concentrations and AUC’s are obtained after each
dose of cyclosporine or tacrolimus, although many med-
ications exhibit chronopharmacokinetics (13). The time-
dependent pharmacokinetics of tacrolimus suggest that
once daily morning administration of tacrolimus may pro-
duce appropriate drug exposure to prevent organ rejection
without significantly increasing toxicity (14). These vari-
ations in tacrolimus absorption suggest that once daily
dosing may be possible at a lower total dose when
given in the morning. Furthermore, taking fewer medica-
tions less frequently may help transplant patients to bet-
ter manage their drug therapy, increase compliance and
lower medication costs. Therefore, the purpose of this
pilot study was to compare pharmacokinetics and safety
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of twice daily vs. once daily oral administration of
tacrolimus in stable kidney transplant recipients.
Materials and Methods
Patients
Inclusion criteria consisted of kidney transplant recipients (18 years or older)
at Washington University/Barnes-Jewish Hospital taking tacrolimus-based
immunosuppression with stable kidney function (greater than 6 months
post-transplantation, serum creatinine <2 mg/dL, no history of rejection)
and stable immunosuppression (therapeutic tacrolimus concentrations 5–
10 ng/mL, no change in tacrolimus dose within 1 month prior to the study).
Exclusion criteria consisted of pregnant women, nursing mothers, patients
unwilling or unable to comply with the study protocol, patients with signif-
icant liver impairment (serum transaminases or total bilirubin greater than
two times the upper limit of normal), patients with a hematocrit <30%, use
of concomitant cytochrome P450 3A4/P-glycoprotein inducers or inhibitors,
or patients with diabetes mellitus unable to fast overnight. This study was
approved by the Human Studies Committee of Washington University (pro-
tocol number 01–0884).
Study protocol
Steady-state tacrolimus pharmacokinetic parameters were estimated on
two occasions in an open-label, three-arm, two-period, sequential study.
Twenty-four hour pharmacokinetic studies were conducted at the end of
each period (Phase I and II). In phase I of the study, patients were asked to
take their maintenance tacrolimus dose twice daily in equally divided doses.
In phase II, patients were divided into three groups based on their phase II
dosing regimen: those taking 67% of their total twice daily dose once daily
(67% Group), those taking 85% of their total twice daily dose once daily
(85% Group) and those taking 100% of their total twice daily dose once
daily in the morning (100% Group).
In phase I, patients were asked to self-administer their maintenance
tacrolimus at 08.00 and 20.00 hours daily in equally divided doses and
to record the time of intake. On the last day of phase I (day 6), patients
were admitted to the General Clinical Research Center (GCRC) and given
their morning tacrolimus dose with 120 mL of water at approximately 08.00
hours and their evening dose 12 h after the morning dose at approximately
20.00 hours. Serial blood samples (3 mL each) were collected from the in-
dwelling catheter into EDTA-containing tubes at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9,
and 12 h after the morning dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 9, and 12 h af-
ter the evening dose. Throughout the study, aliquots of blood were frozen
and stored at −20 ◦C until analyzed by microparticle enzyme immunoas-
say (MEIA; IMx, Abbott Laboratories, Abbott Park, IL, USA) for tacrolimus
concentration.
In phase II, the tacrolimus dose was calculated based on group assignments
(Group 67%, 85% or 100%) and rounded to commercially available dosage
forms (0.5 mg, 1 mg, and 5 mg capsules). For example, if a patient was
taking tacrolimus 4 mg orally twice daily and assigned to the 67% Group,
then the once daily dose was 5.5 mg (8 mg per day × 67% = 5.36 mg,
rounded to 5.5 mg). Patients were instructed to self-administer their once
daily dose at 08.00 hours. On the last day of phase II (day 14), patients were
admitted to the GCRC and given their daily tacrolimus dose with 120 mL of
water at approximately 08.00 hours. Serial blood samples 3 mL each) were
collected from the indwelling catheter into EDTA-containing tubes at 0, 0.5,
1, 1.5, 2, 3, 4, 6, 9, 12, 16, 20, and 24 h after the dose.
Diet
Patients were asked to abstain from alcohol and caffeine for 48 h prior to
and during the pharmacokinetic studies. To control for the effects of food
on tacrolimus pharmacokinetics (15,16), patients were asked to fast from
22.00 hours on days 5 and 13, prior to the admission to the GCRC. The
exact same diet was given at the same times on both tacrolimus study
days (days 6 and 14). Breakfast was provided 2 h after the morning dose
of tacrolimus at 10.00 hours, lunch at noon, and dinner at 17.00 hours (3 h
prior to the evening dose in phase I). Patients were allowed 30 min for food
consumption. Food and beverage intake was monitored and recorded.
Endpoints
Area under the blood concentration time curve was calculated using the
trapezoidal rule for ascending concentrations and logarithmic trapezoidal
rule for descending concentrations. The primary endpoint was the ratio of
AUC 0–24 between the twice daily and once daily tacrolimus drug exposure.
Secondary endpoints included tacrolimus peak concentration (Cmax .), time
to reach Cmax . (Tmax .), tacrolimus trough concentration (12 h after each dose
on day 6, C12 and C24; 24 h after dose on day 14, C24). Safety assessment
included adverse events as assessed by patient interview and laboratory
parameters which were obtained at baseline and upon completion of the
study.
Statistical analysis
Paired t-tests were used for continuous variables. Pearson’s analysis was
used to assess correlation between AUC and tacrolimus concentration. A
p-value of <0.05 was considered significant.
Results
Eighteen renal transplant recipients were recruited for the
study and equally divided into three groups. Most patients
were female (78%) and Caucasian (90%). The mean age
was 43 ± 14 (range 20–62) (Table 1). There were no differ-
ences in characteristics between the groups.
Table 1: Characteristics of patients
Patient characteristic (n = 18)





Weight (kg) 91 ± 18 (55–123)∗
Height (cm) 169 ± 10 (141–189)∗
Time from transplant (years) 1.8 ± 1.2 (0.5–5)∗
Disease leading to transplant
Polycystic kidney disease 4 (22%)
Glomerulonephritis 4 (22%)
Hypertensive nephrosclerosis 2 (11%)
Reflux nephropathy 2 (11%)
Congenital nephropathy 1 (6%)
Interstitial nephritis 1 (6%)




Tacrolimus + azathioprine + prednisone 8 (44%)
Tacrolimus + mycophenolate 5 (28%)
+prednisone
Tacrolimus + prednisone 5 (28%)
∗Mean ± SD (range).
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Table 2: Summary of pharmacokinetic parameters
Group 67% Group 85% Group 100%
Parameter BID QD BID QD BID QD
Daily dose (mg) 3.8 ± 2.2 2.8 ± 1.5 6.7 ± 3.2 5.7 ± 2.8 6.3 ± 3.9 6.3 ± 3.9
Daily dose (mg/kg) 0.04 ± 0.02 0.03 ± 0.01 0.07 ± 0.01 0.06 ± 0.03 0.08 ± 0.07 0.08 ± 0.07
C12 (ng/mL) 6.6 ± 2.5 4.6 ± 1.9 5.6 ± 1.0 6.5 ± 1.9 5.9 ± 1.8 7.9 ± 2.4
C24 (ng/mL) 5.9 ± 2.3 3.4 ± 1.1 6.0 ± 0.8 4.6 ± 1.3 5.9 ± 2.2 5.6 ± 2.1
Trough ratio (BID/QD) 0.7 ± 0.3 0.8 ± 0.2 1.0 ± 0.2
Cmax.0–24 (ng/mL) 18.1 17.0 17.7 23.4 19.0 24.1
Tmax .0–24 (h) 2.0 1.0 1.5 1.5 1.5 2.0
Cmax.12–24 (ng/mL) 9.1 – 7.7 – 8.5 –
Tmax .12–24 (h) 15.0 – 21.0 – 18.0 –
AUC0–24 (ng/h/mL) 212 ± 81 145 ± 55 201 ± 39 206 ± 56 206 ± 80 242 ± 86
AUC ratio (BID/QD) 0.7 ± 0.1 1.0 ± 0.1 1.2 ± 0.3
AUC0–12 (ng/h/mL) 118 ± 44 95 ± 37 118 ± 29 141 ± 39 116 ± 50 141 ± 83
AUC12–24 (ng/h/mL) 96 ± 38 50 ± 18 83 ± 11 68 ± 18 112 ± 32 79 ± 29
Mean difference (%) 23% 89% 41% 116% 4% 77%
AUC0–12/AUC12–24
BID: twice daily administration; QD: once daily administration in the morning.
Mean ± SD.
Twice daily dosing
In phase I, in all three groups combined, there was a shorter
time to the Tmax. (1.5 vs. 3.0 h) and a higher Cmax. (17.8
vs. 8.4 ng/mL) with morning vs. evening administration,
although C12 and C24 were similar (Table 2, Figure 1). The
mean AUC was higher after the morning dose compared
with the evening dose, AUC0–12 117 ± 40 vs. AUC12–24 97
± 30 ng/h/mL, respectively, p = 0.012. C24 had a strong
correlation with AUC0–24 (R2 = 0.80, Figure 2).
Once daily dosing
In phase II, C12 and C24 increased as the percentage of the
twice daily dose given once daily dose increased (Table 2).
Likewise, the Cmax . and AUC0–24 were higher in the 85%
and 100% Groups when compared with the 67% Group
(Figure 1). The higher Cmax . did not translate into adverse
events. The once daily C24 had a strong correlation with
AUC0–24 (R2 = 0.77, Figure 2).
Twice daily vs. once daily dosing
In the 67% Group, the AUC ratio between twice daily and
approximately 67% of the twice daily dose given once
daily was 0.7 (95% CI, 0.6–0.7) (Table 2) suggesting lower
once daily exposure to tacrolimus. In the 100% Group, the
AUC ratio between the twice daily dose and 100% of the
twice daily dose given once daily was 1.2 (95% CI, 0.9–1.5)
suggesting higher exposure with once daily tacrolimus. In
the 85% Group, the mean AUC ratio was 1.0 (95% CI,
0.9–1.1) between the twice daily and once daily exposure
which predicted the best conversion ratio between once
and twice daily dosing. The mean trough ratio between
twice daily dosing and once daily dosing increased as the
percentage of the once daily dose increased. In the 67%
Group, the mean trough ratio was 0.7 (95% CI, 0.4–1.0),
in the 85% Group 0.8 (95% CI, 0.6–1.0), and in the 100%
Group 1.0 (95% CI, 0.8–1.2).
Safety
No adverse events occurred and patients did not report
side-effects to the new dosing strategy. The mean serum
creatinine was statistically lower on Day 14 with once daily
administration (1.34 ± 0.33 mg/dL, Day 6 vs. 1.26 ± 0.35
mg/dL, Day 14, p = 0.011).
Follow-up
Most (16/18) patients have been maintained on once daily
tacrolimus for at least 6 months (range 6–18 months). The
average maintenance conversion dose was 85% of the
twice daily dose, 5.8 ± 3.4 mg/day before conversion vs.
4.9 ± 2.7 mg/day after conversion. No rejection episodes
have occurred during this time period and the mean serum
creatinine has been maintained, 1.27 ± 0.29 mg/dL, at
6 months post-conversion.
Discussion
The results of this study demonstrate that tacrolimus given
once daily at 85% of the twice daily dose provides safe
and equivalent drug exposure to twice daily dosing. Fur-
thermore, the tacrolimus concentration 24 h (C24) after the
dose provides a strong marker for once daily drug expo-
sure.
In phase I of the study, evening absorption of tacrolimus
was impaired, as exhibited by the lower evening Cmax .
and AUC seen in twice daily dosing. One explanation for
the lower evening AUC is the decreased oral bioavailabil-
ity of tacrolimus when taken with food. Several studies
have reported that the oral bioavailability of tacrolimus is
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Figure 1: Tacrolimus blood concentration–time profile of a
representative subject from each dosing regimen. In the 67%
Group, the area under the blood concentration-time curve (AUC)
ratio between twice daily and once daily was 0.680. In the 100%
Group, the AUC ratio between twice daily dose and once daily was
1.227. In the 85% Group the mean AUC ratio was 1.025 between
the twice daily and once daily exposure, thus predicted the best
conversion ratio between once and twice daily dosing.
altered after food consumption (15–17). An increase in
Cmax . (15–40%) and AUC (2–12%) have been reported in a
fasting state vs. a nonfasting state (15–17). Furthermore,
the time of tacrolimus administration with respect to a meal
has been reported to effect bioavailability of tacrolimus
(15,16). It is possible that in Phase I of the trial the evening
dose of tacrolimus had altered bioavailability because food
Twice daily dosing (BID)
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Figure 2: Correlation between tacrolimus concentration and
area under the concentration-time curve (AUC). C24 has a
strong correlation with drug exposure (AUC0–24) with both twice
daily (R2 = 0.80) and once daily (R2 = 0.77) dosing.
was allowed from 2.5 to 3 h prior to the evening dose,
whereas for the morning dose patients were asked to fast
for 10 h prior to administration. The manufacturer recom-
mends that tacrolimus be taken 1 h before or 2 h after a
meal, but it is possible that even minimal food retention in
the gastrointestinal tract altered the evening absorption of
tacrolimus.
Additionally, circadian variations in absorption and disposi-
tion of oral tacrolimus may help to explain our results (14).
In a study of 12 stable liver transplant recipients, mean AUC
after the morning dose was greater than after the evening
dose (219 ± 54 ng/h/mL vs. 188 ± 57 ng/h/mL, p = 0.004).
Likewise, the mean Cmax . was higher after the morning
dose than after the evening dose (32.2 ± 9.1 ng/mL vs.
21.6 ± 8.3 ng/mL, p = 0.008). However, the mean Cmin.
was similar between the doses (13.5 ± 4.7 ng/mL vs.
624 American Journal of Transplantation 2004; 4: 621–625
Once Daily Tacrolimus
13.3 ± 5.2 ng/mL, p = 0.9). It is noteworthy that 7 out of
12 patients (58%) showed no apparent peak in tacrolimus
concentrations with the evening dose. Our trial confirms
these findings.
Similar drug exposure with once daily dosing in the morn-
ing was achieved in our study without added toxicity. Fur-
thermore, the higher Cmax . achieved in the 85% and 100%
Groups did not correlate with adverse events. This is sup-
ported by a phase III trial in kidney transplant recipients that
evaluated the correlation of tacrolimus Cmax . and toxicity.
Of 205 study patients, 181 had at least one peak concen-
tration reported within the first year of the trial. For pa-
tients with more than one peak drawn, the highest value
was used in the analysis. No correlation was found be-
tween Cmax . and neurotoxicity, tremor, diarrhea, nephro-
toxicity, increased serum creatinine, hyperglycemia, dia-
betes, or biopsy-confirmed acute rejection (P. Blahunka,
Fujisawa, Deerfield, IL, USA, personal communication,
12/01).
Whether it was due to the effect of food on tacrolimus
bioavailability or circadian variations in absorption, this pi-
lot study of stable renal transplant recipients demonstrates
that the superior absorption of tacrolimus in the morning al-
lows tacrolimus to be taken once daily at a lower dose. Fur-
thermore, this pharmacokinetic analysis demonstrates that
tacrolimus given once daily is safe and effective in select
patients that are at low risk of rejection (no history of acute
rejection, stable renal function, at least 6 months from
transplant, Caucasian recipients) under controlled circum-
stances (nondiabetic patients, restricted food consump-
tion, no interacting medications). Lastly, this study demon-
strated that a 24-h trough concentration (C24) was a good
marker for total drug exposure (AUC). Although, this dosing
strategy was safe and effective in this pilot trial of select pa-
tients, further study is warranted. This convenient dosing
schedule may allow transplant patients to better manage
their drug therapy, increase compliance and lower medica-
tion costs.
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